Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 22, 2020

View Archived Issues

A stinging defeat for infections

Researchers develop a new murine model of seizures with Chd8 haploinsufficiency

DUSP6 is implicated in vascular disease and may be a therapeutic target

Abpro completes dosing in phase I trial of ABP-300 for COVID-19

Optimization of selective antagonists of vasopressin V1A receptor derived from triazolobenzazepines

Hyaluronan is present in the alveolar spaces in lungs of patients with fatal COVID-19

SARS-CoV-2 RNA genome can be targeted using small-molecule binders and RIBOTAC degraders

Phase III study of masitinib in severe asthma uncontrolled by ICS meets primary endpoint

Oxeia initiates phase II study of OXE-103 for concussions

Storm Therapeutics patents METTL3 inhibitors

Centauri Therapeutics divulges new antibacterials

Array BioPharma presents new PTPN11 inhibitors

First patient enrolled in MERKLIN 2 trial of domatinostat plus avelumab in MCC

New CDK inhibitors presented by Aurigene Discovery Technologies

Sorrento Therapeutics patents CD38-targeting antibodies

Poseida and TScan collaborate to develop TCR-T cell therapies for treatment of COVID-19

Second part of daratumumab CASSIOPEIA study in multiple myeloma meets primary endpoint

First-in-human injection of [68]Ga-NT-20.3 found to be well-tolerated without AEs

Phase I data presented for RP-L201 in patients with LAD-I

Gene therapy approaches tackle multiple forms of blindness

FDA clears Cyclo to open global phase III trial of Trappsol Cyclo for NPC in U.S.

MAb 5D3-mertansine antibody-drug conjugate shows efficacy in prostate cancer mouse models

Ultimovacs reports 5-year OS data from phase I trial of UV-1 in NSCLC

Nanoform targets initiation of first-in-human trial of nanoformed piroxicam before year-end

Daiichi initiates phase I trial of DS-1055 in advanced or metastatic solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...